A Supreme Court case initiated by surgeon Sanjay Kulshrestha is questioning the government's narrow focus on anti-cancer drug price caps. With approximately 76% of new drugs currently operating outside official ceiling price regulations, investors are watching whether the court might mandate a broader review of pricing mechanisms. Such a shift could potentially impact profit margins for pharmaceutical companies with large portfolios of non-scheduled medications.
The Supreme Court is currently hearing a challenge regarding the government’s approach to pharmaceutical pricing, specifically questioning why regulatory oversight is heavily focused on anti-cancer medications while ignoring a vast segment of the market. The petitioner, paediatric surgeon Sanjay Kulshrestha, has argued that the current framework is fragmented and fails to address excessive mark-ups in other critical therapeutic areas. This legal development comes shortly after the Union Ministry of Chemicals and Fertilisers announced the formation of an expert committee on October 9, 2026, aimed at evaluating trade margin rationalisation for cancer drugs.
At the heart of the investor concern is the distinction between 'scheduled' and 'non-scheduled' drugs. Under the current Drugs (Prices Control) Order, 2013, the government sets ceiling prices for essential medicines. However, data highlighted in the petition suggests that only about 24% of new drug launches currently fall under these price-controlled categories. This leaves roughly 76% of the market to operate without direct price ceilings, allowing companies to set their own pricing strategies. The petitioner contends that this regulatory gap enables significant mark-ups throughout the supply chain, which can reach high levels for certain medications.
The pharmaceutical sector in India frequently uses high-margin, non-scheduled products to balance the lower margins mandated on essential, price-controlled drugs. If the Supreme Court directs the government to expand its price control mechanism beyond oncology to other high-volume categories like cardiac, anti-diabetic, and antibiotic treatments, it could create a significant shift in the operational environment. For investors, this creates a potential risk of margin compression, particularly for companies that generate a substantial portion of their revenue from non-scheduled medications that might eventually be brought under regulatory scrutiny.
The government has maintained that its current focus on oncology is a targeted effort to improve affordability for critical care. However, the petition pushes for a more systemic review involving expertise from both health and tax departments to address pricing loopholes across all therapeutic segments. As the court proceedings continue, the key monitorable for market participants will be any judicial directive that could force the National Pharmaceutical Pricing Authority to expand its scope of regulation. Investors may also track whether such a move would lead to a broader, sector-wide reset on profit margins, or if the court will uphold the government’s current segmented approach to drug pricing.